Depression – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Depression – Pipeline Review, H2 2016’, provides an overview of the Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Depression

The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Depression therapeutics and enlists all their major and minor projects

The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Depression

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Depression

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

Acetylon Pharmaceuticals, Inc.

Ache Laboratorios Farmaceuticos S/A

Adamed Sp. z o.o.

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc.

Alkermes Plc

Allergan Plc

Alvogen Korea Co., Ltd.

Amorsa Therapeutics Inc.

Anavex Life Sciences Corp.

Angelini Group

Angita B.V.

Araim Pharmaceuticals, Inc.

AstraZeneca Plc

Avanir Pharmaceuticals, Inc.

Axsome Therapeutics Inc

Azevan Pharmaceuticals, Inc.

BioCrea GmbH

Biogen Inc

Biohaven Pharmaceutical Holding Company Limited

BioLite, Inc.

Bionomics Limited

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Calico LLC

Celon Pharma Sp. z o.o.

Cerecor Inc.

Clera Inc.

D-Pharm Ltd.

Delpor, Inc.

e-Therapeutics Plc

Eisai Co., Ltd.

Eli Lilly and Company

Evotec AG

Fabre-Kramer Pharmaceuticals, Inc.

GlaxoSmithKline Plc

GliaCure Inc.

H. Lundbeck A/S

Heptares Therapeutics Limited

Hua Medicine (Shanghai) Ltd.

Hyundai Pharmaceutical Co., Ltd.

Impel NeuroPharma, Inc.

INSYS Therapeutics, Inc.

Intas Pharmaceuticals Ltd.

Intra-Cellular Therapies, Inc.

INVENT Pharmaceuticals, Inc.

Johnson & Johnson

KemPharm, Inc.

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lixte Biotechnology Holdings, Inc.

Luye Pharma Group Ltd.

Mapi Pharma Ltd.

Mapreg S.A.S.

Meta-IQ ApS

Methylation Sciences Inc.

miCure Therapeutics Ltd.

Mitsubishi Tanabe Pharma Corporation

Navya Biologicals Pvt Ltd

Neuralstem, Inc.

Neurocrine Biosciences, Inc.

NeuroNascent, Inc.

NeurOp, Inc

Newron Pharmaceuticals S.p.A.

Nippon Chemiphar Co., Ltd.

nLife Therapeutics, S.L.

Novartis AG

Omeros Corporation

Otsuka Holdings Co., Ltd.

Pfizer Inc.

Pherin Pharmaceuticals, Inc.

Polleo Pharma Limited

Protagenic Therapeutics Inc.

Relmada Therapeutics, Inc.

Reviva Pharmaceuticals Inc.

Richter Gedeon Nyrt.

Saniona AB

SK Biopharmaceuticals Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Supernus Pharmaceuticals, Inc.

Suven Life Sciences Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

Takeda Pharmaceutical Company Limited

Tetra Discovery Partners LLC

Trevena, Inc.

TRImaran Pharma, Inc.

Turing Pharmaceuticals AG

VistaGen Therapeutics , Inc.

Zhejiang Huahai Pharmaceutical Co., Ltd.

Zogenix, Inc.

Zysis Limited

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Depression Overview 9

Therapeutics Development 10

Depression - Therapeutics under Development by Companies 12

Depression - Therapeutics under Investigation by Universities/Institutes 20

Depression - Pipeline Products Glance 22

Depression - Products under Development by Companies 26

Depression - Products under Investigation by Universities/Institutes 37

Depression - Companies Involved in Therapeutics Development 39

Depression - Therapeutics Assessment 131

Drug Profiles 151

Depression - Dormant Projects 432

Depression - Discontinued Products 457

Depression - Product Development Milestones 465

Appendix 474

List of Tables

List of Tables

Number of Products under Development for Depression, H2 2016 29

Number of Products under Development for Depression – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 32

Number of Products under Development by Companies, H2 2016 (Contd..1) 33

Number of Products under Development by Companies, H2 2016 (Contd..2) 34

Number of Products under Development by Companies, H2 2016 (Contd..3) 35

Number of Products under Development by Companies, H2 2016 (Contd..4) 36

Number of Products under Development by Companies, H2 2016 (Contd..5) 37

Number of Products under Development by Companies, H2 2016 (Contd..6) 38

Number of Products under Investigation by Universities/Institutes, H2 2016 40

Comparative Analysis by Late Stage Development, H2 2016 41

Comparative Analysis by Clinical Stage Development, H2 2016 42

Comparative Analysis by Early Stage Development, H2 2016 43

Comparative Analysis by Unknown Stage Development, H2 2016 44

Products under Development by Companies, H2 2016 45

Products under Development by Companies, H2 2016 (Contd..1) 46

Products under Development by Companies, H2 2016 (Contd..2) 47

Products under Development by Companies, H2 2016 (Contd..3) 48

Products under Development by Companies, H2 2016 (Contd..4) 49

Products under Development by Companies, H2 2016 (Contd..5) 50

Products under Development by Companies, H2 2016 (Contd..6) 51

Products under Development by Companies, H2 2016 (Contd..7) 52

Products under Development by Companies, H2 2016 (Contd..8) 53

Products under Development by Companies, H2 2016 (Contd..9) 54

Products under Development by Companies, H2 2016 (Contd..10) 55

Products under Investigation by Universities/Institutes, H2 2016 56

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 57

Depression – Pipeline by AB Science SA, H2 2016 58

Depression – Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 59

Depression – Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 60

Depression – Pipeline by Adamed Sp. z o.o., H2 2016 61

Depression – Pipeline by Addex Therapeutics Ltd, H2 2016 62

Depression – Pipeline by Aequus Pharmaceuticals Inc., H2 2016 63

Depression – Pipeline by Alkermes Plc, H2 2016 64

Depression – Pipeline by Allergan Plc, H2 2016 65

Depression – Pipeline by Alvogen Korea Co., Ltd., H2 2016 66

Depression – Pipeline by Amorsa Therapeutics Inc., H2 2016 67

Depression – Pipeline by Anavex Life Sciences Corp., H2 2016 68

Depression – Pipeline by Angelini Group, H2 2016 69

Depression – Pipeline by Angita B.V., H2 2016 70

Depression – Pipeline by Araim Pharmaceuticals, Inc., H2 2016 71

Depression – Pipeline by AstraZeneca Plc, H2 2016 72

Depression – Pipeline by Avanir Pharmaceuticals, Inc., H2 2016 73

Depression – Pipeline by Axsome Therapeutics Inc, H2 2016 74

Depression – Pipeline by Azevan Pharmaceuticals, Inc., H2 2016 75

Depression – Pipeline by BioCrea GmbH, H2 2016 76

Depression – Pipeline by Biogen Inc, H2 2016 77

Depression – Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016 78

Depression – Pipeline by BioLite, Inc., H2 2016 79

Depression – Pipeline by Bionomics Limited, H2 2016 80

Depression – Pipeline by Boehringer Ingelheim GmbH, H2 2016 81

Depression – Pipeline by Bristol-Myers Squibb Company, H2 2016 82

Depression – Pipeline by Calico LLC, H2 2016 83

Depression – Pipeline by Celon Pharma Sp. z o.o., H2 2016 84

Depression – Pipeline by Cerecor Inc., H2 2016 85

Depression – Pipeline by Clera Inc., H2 2016 86

Depression – Pipeline by D-Pharm Ltd., H2 2016 87

Depression – Pipeline by Delpor, Inc., H2 2016 88

Depression – Pipeline by e-Therapeutics Plc, H2 2016 89

Depression – Pipeline by Eisai Co., Ltd., H2 2016 90

Depression – Pipeline by Eli Lilly and Company, H2 2016 91

Depression – Pipeline by Evotec AG, H2 2016 92

Depression – Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016 93

Depression – Pipeline by GlaxoSmithKline Plc, H2 2016 94

Depression – Pipeline by GliaCure Inc., H2 2016 95

Depression – Pipeline by H. Lundbeck A/S, H2 2016 96

Depression – Pipeline by Heptares Therapeutics Limited, H2 2016 97

Depression – Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016 98

Depression – Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 99

Depression – Pipeline by Impel NeuroPharma, Inc., H2 2016 100

Depression – Pipeline by INSYS Therapeutics, Inc., H2 2016 101

Depression – Pipeline by Intas Pharmaceuticals Ltd., H2 2016 102

Depression – Pipeline by Intra-Cellular Therapies, Inc., H2 2016 103

Depression – Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 104

Depression – Pipeline by Johnson & Johnson, H2 2016 105

Depression – Pipeline by KemPharm, Inc., H2 2016 106

Depression – Pipeline by Lead Discovery Center GmbH, H2 2016 107

Depression – Pipeline by Les Laboratoires Servier SAS, H2 2016 108

Depression – Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 109

Depression – Pipeline by Luye Pharma Group Ltd., H2 2016 110

Depression – Pipeline by Mapi Pharma Ltd., H2 2016 111

Depression – Pipeline by Mapreg S.A.S., H2 2016 112

Depression – Pipeline by Meta-IQ ApS, H2 2016 113

Depression – Pipeline by Methylation Sciences Inc., H2 2016 114

Depression – Pipeline by miCure Therapeutics Ltd., H2 2016 115

Depression – Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 116

Depression – Pipeline by Navya Biologicals Pvt Ltd, H2 2016 117

Depression – Pipeline by Neuralstem, Inc., H2 2016 118

Depression – Pipeline by Neurocrine Biosciences, Inc., H2 2016 119

Depression – Pipeline by NeuroNascent, Inc., H2 2016 120

Depression – Pipeline by NeurOp, Inc, H2 2016 121

Depression – Pipeline by Newron Pharmaceuticals S.p.A., H2 2016 122

Depression – Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 123

Depression – Pipeline by nLife Therapeutics, S.L., H2 2016 124

Depression – Pipeline by Novartis AG, H2 2016 125

Depression – Pipeline by Omeros Corporation, H2 2016 126

Depression – Pipeline by Otsuka Holdings Co., Ltd., H2 2016 127

Depression – Pipeline by Pfizer Inc., H2 2016 128

Depression – Pipeline by Pherin Pharmaceuticals, Inc., H2 2016 129

Depression – Pipeline by Polleo Pharma Limited, H2 2016 130

Depression – Pipeline by Protagenic Therapeutics Inc., H2 2016 131

Depression – Pipeline by Relmada Therapeutics, Inc., H2 2016 132

Depression – Pipeline by Reviva Pharmaceuticals Inc., H2 2016 133

Depression – Pipeline by Richter Gedeon Nyrt., H2 2016 134

Depression – Pipeline by Saniona AB, H2 2016 135

Depression – Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 136

Depression – Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 137

Depression – Pipeline by Supernus Pharmaceuticals, Inc., H2 2016 138

Depression – Pipeline by Suven Life Sciences Ltd., H2 2016 139

Depression – Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 140

Depression – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 141

Depression – Pipeline by Tetra Discovery Partners LLC, H2 2016 142

Depression – Pipeline by Trevena, Inc., H2 2016 143

Depression – Pipeline by TRImaran Pharma, Inc., H2 2016 144

Depression – Pipeline by Turing Pharmaceuticals AG , H2 2016 145

Depression – Pipeline by VistaGen Therapeutics , Inc., H2 2016 146

Depression – Pipeline by Zhejiang Huahai Pharmaceutical Co., Ltd., H2 2016 147

Depression – Pipeline by Zogenix, Inc., H2 2016 148

Depression – Pipeline by Zysis Limited, H2 2016 149

Assessment by Monotherapy Products, H2 2016 150

Assessment by Combination Products, H2 2016 151

Number of Products by Stage and Target, H2 2016 153

Number of Products by Stage and Mechanism of Action, H2 2016 160

Number of Products by Stage and Route of Administration, H2 2016 167

Number of Products by Stage and Molecule Type, H2 2016 169

Depression – Dormant Projects, H2 2016 451

Depression – Dormant Projects (Contd..1), H2 2016 452

Depression – Dormant Projects (Contd..2), H2 2016 453

Depression – Dormant Projects (Contd..3), H2 2016 454

Depression – Dormant Projects (Contd..4), H2 2016 455

Depression – Dormant Projects (Contd..5), H2 2016 456

Depression – Dormant Projects (Contd..6), H2 2016 457

Depression – Dormant Projects (Contd..7), H2 2016 458

Depression – Dormant Projects (Contd..8), H2 2016 459

Depression – Dormant Projects (Contd..9), H2 2016 460

Depression – Dormant Projects (Contd..10), H2 2016 461

Depression – Dormant Projects (Contd..11), H2 2016 462

Depression – Dormant Projects (Contd..12), H2 2016 463

Depression – Dormant Projects (Contd..13), H2 2016 464

Depression – Dormant Projects (Contd..14), H2 2016 465

Depression – Dormant Projects (Contd..15), H2 2016 466

Depression – Dormant Projects (Contd..16), H2 2016 467

Depression – Dormant Projects (Contd..17), H2 2016 468

Depression – Dormant Projects (Contd..18), H2 2016 469

Depression – Dormant Projects (Contd..19), H2 2016 470

Depression – Dormant Projects (Contd..20), H2 2016 471

Depression – Dormant Projects (Contd..21), H2 2016 472

Depression – Dormant Projects (Contd..22), H2 2016 473

Depression – Dormant Projects (Contd..23), H2 2016 474

Depression – Dormant Projects (Contd..24), H2 2016 475

Depression – Discontinued Products, H2 2016 476

Depression – Discontinued Products (Contd..1), H2 2016 477

Depression – Discontinued Products (Contd..2), H2 2016 478

Depression – Discontinued Products (Contd..3), H2 2016 479

Depression – Discontinued Products (Contd..4), H2 2016 480

Depression – Discontinued Products (Contd..5), H2 2016 481

Depression – Discontinued Products (Contd..6), H2 2016 482

Depression – Discontinued Products (Contd..7), H2 2016 483

List of Figures

List of Figures

Number of Products under Development for Depression, H2 2016 29

Number of Products under Development for Depression – Comparative Analysis, H2 2016 30

Number of Products under Development by Companies, H2 2016 31

Number of Products under Investigation by Universities/Institutes, H2 2016 39

Comparative Analysis by Late Stage Development, H2 2016 41

Comparative Analysis by Clinical Stage Development, H2 2016 42

Comparative Analysis by Early Stage Products, H2 2016 43

Assessment by Monotherapy Products, H2 2016 150

Assessment by Combination Products, H2 2016 151

Number of Products by Top 10 Targets, H2 2016 152

Number of Products by Stage and Top 10 Targets, H2 2016 152

Number of Products by Top 10 Mechanism of Actions, H2 2016 159

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 159

Number of Products by Top 10 Routes of Administration, H2 2016 166

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 166

Number of Products by Top 10 Molecule Types, H2 2016 168

Number of Products by Stage and Top 10 Molecule Types, H2 2016 168

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports